By PLM Investments : Novo Nordisk ( NVO ) is generally recognized as one ..... ongoing oral clinical efforts by Novo that should complete by the end of the year. Novo 's oral diabetes drug development
Orexigen, is likely to see its anti-obesity drug approved this Fall. There are other players in the space as well. Novo Nordisk ( NVO ) is seeking an anti-obesity label for its diabetes drug, Victoza, which already has impressive sales, and Zafgen
cancer in former smokers prompted diabetes experts such as Novo Nordisk and Eli Lilly to discontinue their inhaled insulin products ..... insulin class with a negative stigma. Diabetes giants such as Novo and Lilly have pulled their inhaled insulins from development
much as $1 million, and works only 70% of the time; if ITI fails, patients must move to a bypass therapy, like Novo Nordisk 's NVO NovoSeven or Baxter's Feiba, for life. We think Biogen lacks the long-term data in previously untreated patients
June 14 (Reuters) - Novo Nordisk 's big-selling diabetes drug Victoza appears to be an effective weight loss therapy, data from a late-stage clinical trial presented on Saturday demonstrated.
June 14 (Reuters) - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza maintained superior blood sugar reduction after one year than either...
to continue supporting the dividend payments.Lilly has been steadily losing share in the insulin market because of Novo Nordisk 's more effective marketing and the success of its long-acting and rapid-acting insulin analogs.The patent loss
Novo Nordisk reported first-quarter results that were ..... top-line growth rate for 2014. However, Novo is maintaining its operating profit growth ..... fairly valued at recent prices. We think Novo 's strong portfolio of diabetes therapies
Biogen Idec and Novo Nordisk are taking aim at Baxter's Advate, and a less-frequent ..... competition for Advate from the likes of Biogen Idec and Novo Nordisk over the next few years could begin to erode the firm's
than growth in more recent years ( Novo Nordisk NVO cites a 14.1% five-year historical ..... AstraZeneca 's AZN Byetta/Bydureon, Novo 's Victoza, Sanofi's Lyxumia ..... insulin players Sanofi, Lilly, and Novo Nordisk . As a result of their wide economic